兰德-Population_78页_1007kb

Summary of "Population-scale sequencing and the future of genomic medicine"

Core Content

This report explores the development and implications of population-scale genome-sequencing initiatives over the past two decades. It highlights how these efforts have created new opportunities for genomic medicine, which aims to improve disease prevention, management, and treatment through the application of genetic data. While the field has made significant scientific and technological progress, the routine integration of genomic medicine into clinical care remains a future goal due to various scientific, social, regulatory, and ethical challenges.

The report focuses on the evolution of these initiatives, their diverse aims and objectives, and the broader social and institutional impacts they have had. It also outlines a future research and policy agenda to support the continued development of genomic medicine.

Main Points

1. Diversity in Aims and Objectives

Population-scale sequencing initiatives have varied objectives, including:

• Advancing knowledge on genetic variation within and across populations.
• Enriching disease-specific insights for diagnosis, risk prediction, and treatment.
• Developing new tools and methods for genetic research.
• Building capacity in human resources, management, and infrastructure.
• Catalysing translation and coordination between initiatives.
• Supporting national security, surveillance, and commercial services.

2. Scope and Scale of Activities

These initiatives differ in:

• Geographic scope: Some are national, while others are international.
• Data collection: Ranging from broad population studies to disease-specific or rare disorder-focused projects.
• Data usage: Including open-access policies, delayed data release provisions, and data-sharing frameworks.
• Partnerships: Often involving academic institutions, government bodies, and private companies.

3. Funding and Partnerships

• The majority of funding comes from public and third-sector players.
• Public-private partnerships are increasingly common, especially in countries aiming to lead in genomic research.
• Most projects are conducted within academic and research institutions, with some outsourcing sequencing to specialist firms like BGI and Illumina.
• Only a few initiatives involve direct private-sector collaboration in research.

4. Data Ownership, Management, and Ethics

• Initiatives have developed various approaches to data ownership and management, including open-access policies and data anonymisation.
• There is ongoing debate around the ethical implications of data sharing, informed consent, and incidental findings.
• Some initiatives provide full feedback on research findings, while others limit feedback to core research aims or exclude it altogether.
• Legal and ethical frameworks for genomic research are still evolving, with challenges in balancing data security, privacy, and access.

5. Scientific and Technological Progress

• Advances in sequencing technologies have significantly reduced costs and time required for genome sequencing.
• The Human Genome Project (1990–2003) laid the foundation for future research, and subsequent projects have expanded on this.
• Initiatives such as the HapMap Consortium and the 1000 Genomes Project have contributed to the development of large-scale datasets that are crucial for genome-wide association studies (GWAS) and other research.

Key Findings

• Scientific Contributions:

  • Population-specific genetic variation catalogues have enabled more targeted disease research.
  • Biobank-based projects provide longitudinal datasets that help understand gene-environment interactions.
  • GWAS has been instrumental in identifying genetic markers for diseases, although it faces criticism regarding study design and assumptions about complex disease biology.

• Clinical Impact:

  • Progress in interpreting genetic variation is starting to influence clinical practice, particularly in diagnosing rare disorders.
  • Some projects, such as the Icelandic deCODE genetics and Estonia's whole-exome sequencing initiatives, have shown early promise in clinical applications.

• Institutional and Social Implications:

  • These initiatives have influenced research ethics, informed consent practices, and data-sharing norms.
  • They have sparked debates on the balance between data security, privacy, and the need for broader access to data.
  • Legal frameworks for genomic medicine are still in their early stages, with cases like the lawsuit over hereditary brain disease highlighting the need for clearer regulations.

Future Research and Policy Agenda

The report identifies five key areas for future action:

1. Scaling International Collaboration: Encourage interdisciplinary and cross-sector collaboration to enable better interpretation of large-scale genomic data.
2. Research on Genomic Interventions: Explore the health-economic, implementation, and communication implications of genomic interventions in clinical settings.
3. R&D Model Evolution: Examine how industry R&D models and public-private investment rationales may change in the genomic medicine era.
4. Research Ethics and Legal Frameworks: Develop and refine ethical and legal frameworks for genomic data management, informed consent, and data sharing.
5. Accountability and Learning: Implement comprehensive evaluation mechanisms for ongoing and completed initiatives to ensure accountability and effective progress in genomic medicine.

Key Initiatives

The following 30 initiatives are profiled in the report:

• International:

  • The Human Genome Diversity Project (HGDP)
  • The International HapMap Consortium
  • The Global Network of Personal Genome Projects (PGP)
  • The 1000 Genomes Project
  • The Human Heredity and Health in Africa (H3Africa) Initiative
  • The African Genome Variation Project
  • The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium
  • The International Cancer Genome Consortium (ICGC)

• National:

  • deCODE genetics (Iceland)
  • The Estonian Biobank / Estonian Genome Centre, University of Tartu (EGCUT)
  • The Singapore Genome Variation Project
  • The Genome of the Netherlands (GoNL)
  • GenomeDenmark
  • The Faroe Genome Project (FarGen)
  • Cymru DNA Wales
  • The National Centre for Indigenous Genomics (NCIG) (Australia)
  • Kuwait legislation introducing mandatory DNA testing
  • The Precision Medicine Initiative Cohort Program (U.S.)
  • SardiNIA
  • China Kadoorie Biobank (CKB)
  • UK Biobank
  • The Slim Initiative in Genomic Medicine for the Americas (SIGMA) (Mexico)
  • UK10K
  • The Deciphering Developmental Disorders (DDD) Study (UK)
  • Genomics England (The 100,000 Genomes Project)
  • A Weill Cornell Medical Study – Exome Sequencing Identifies Potential Risk Variants for Mendelian Disorders at High Prevalence in Qatar
  • The Saudi National Genome Program
  • The Belgium Medical Genomics Initiative (BeMGI)
  • The Initiative on Rare and Undiagnosed Diseases (Japan)
  • The National Centre for Excellence in Research in Parkinson's Disease (NCER-PD) (Luxembourg)

Conclusion

Population-scale sequencing initiatives have played a crucial role in advancing genomic medicine, but their success depends on overcoming a range of scientific, ethical, legal, and social challenges. The report underscores the need for continued investment in research, improved policy frameworks, and greater collaboration to ensure that the potential of genomic medicine is realised in a responsible and effective manner.